Racheon

Cover Block

PUBLIC

Attribute	Detail
Company Name	Racheon
Tagline	Solving IV push medication errors with SentryFLO, an integrated flow rate control device.
Headquarters	Mandeville, LA
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware

Links

PUBLIC

• Website: https://racheon.com/

Data Accuracy: GREEN -- Confirmed by direct retrieval of the company homepage.

Executive Summary

PUBLIC Racheon is a healthtech company aiming to reduce intravenous push medication errors with its SentryFLO device, a hardware solution that would, if successfully developed and commercialized, address a persistent and costly source of patient harm in clinical settings [racheon.com, retrieved 2024]. The company's proposition is defined by a clear, single-product focus on a known safety gap, though its operational and financial footprint remains opaque to public scrutiny. Based in Mandeville, Louisiana, Racheon has filed a trademark for SentryFLO, described as an integrated flow rate control device for drug delivery, specifically syringes sold empty [trademarkelite.com, Apr 7, 2026]. No information regarding the founding team, their backgrounds, or the company's inception date is available in public records, and searches across major business databases yield no identifiable startup profile under this name [Perplexity Sonar Pro Brief]. Capitalization is not publicly disclosed, with no confirmed funding rounds, investors, or revenue metrics. Over the next 12-18 months, the critical watchpoints are the transition of the trademark from an 'intent-to-use' filing to a commercially available product, any announcements of clinical validation or pilot partnerships, and the emergence of a verifiable leadership team with medical device experience. Data Accuracy: YELLOW -- Product claims and trademark are confirmed; all other dimensions lack independent corroboration.

Taxonomy Snapshot

Axis	Value
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Headquarters	Mandeville, LA

Company Overview

PUBLIC

Racheon's corporate identity is defined by its public-facing website and a recent trademark filing, which together outline a healthtech mission but leave foundational details unverified. The company states its purpose is solving IV push medication errors with a device called SentryFLO, aiming to improve patient outcomes [racheon.com, retrieved 2024]. Its headquarters are listed in Mandeville, Louisiana, a detail corroborated by a trademark registration address [trademarkelite.com, April 2026].

Beyond this, the public record is sparse. No founding date, founding team, or legal entity registration for a company named Racheon appears in standard venture databases or corporate registries. Searches across major business platforms return individuals with similar names or unrelated companies, but no identifiable startup profile matching this entity [Perplexity Sonar Pro Brief]. The trademark for SENTRYFLO, filed in October 2025 and published for opposition in April 2026, stands as the most concrete recent milestone, indicating active development of the brand [trademarkelite.com, April 2026].

Data Accuracy: YELLOW -- Core mission and HQ location are confirmed via company website and trademark filing; all other company details are unverified or absent from public sources.

Product and Technology

MIXED

The company's public product definition is narrow and specific. Racheon's stated mission is to solve IV push medication errors, a critical safety problem in clinical settings, with its device named SentryFLO [racheon.com, retrieved 2024]. The product is described as an integrated flow rate control device, which suggests a hardware component designed to regulate the speed at which intravenous medications are manually administered by a clinician [racheon.com, retrieved 2024]. A trademark filing from April 2026 provides a more granular classification, listing SentryFLO as a drug delivery device, specifically syringes, sold empty [trademarkelite.com, Apr 7, 2026]. This indicates the product is likely a specialized syringe or syringe attachment intended to replace or augment standard manual push syringes.

Beyond these core descriptors, technical specifications, software capabilities, and integration details are not publicly available. The term "integrated" in the tagline implies a connection between hardware and software, but the nature of that integration,whether it involves data logging, connectivity to hospital systems, or closed-loop feedback,is not defined in open sources. There is no public documentation of clinical trials, regulatory clearances, or user manuals that would substantiate the product's functional claims or technological maturity.

Data Accuracy: YELLOW -- Product claims are sourced directly from the company's website and a trademark filing, but technical details and independent validation are absent.

Market Research

PUBLIC The market for IV push medication safety is defined by a persistent, high-stakes clinical error that has proven resistant to manual protocols alone, creating a clear opening for hardware-based solutions.

Quantifying the total addressable market for a device like SentryFLO requires inference from adjacent, well-documented categories. The global market for smart syringes and drug delivery devices, which includes safety-engineered and connected injection systems, was valued at approximately $8.5 billion in 2023 and is projected to grow at a compound annual rate of 8-10% through the decade, driven by regulatory mandates and infection prevention efforts [Grand View Research, 2023]. The specific segment for IV push safety devices is narrower but sits within this larger, expanding hardware category. A more direct analog is the market for infusion pump safety devices, which addresses a similar clinical workflow and error profile; this market was estimated at over $15 billion globally in 2022 [Fortune Business Insights, 2022]. These analogous figures suggest a substantial underlying economic activity in the safety-critical medical device space where Racheon aims to operate.

Smart Syringes & Drug Delivery (2023) | 8.5 | $B
Infusion Pump Safety Devices (2022) | 15.1 | $B

The sizing data, while not specific to IV push errors, indicates the scale of investment flowing toward technologies designed to mitigate procedural risks in medication administration.

Demand is anchored in a well-documented clinical problem. Intravenous push medication errors, involving incorrect administration rates or doses, are a recognized source of patient harm, including adverse drug events and cardiac complications. The primary driver is the reliance on manual, nurse-controlled syringe plunger pressure, a technique vulnerable to human variability under high-stress conditions. Regulatory tailwinds are also material. In the United States, The Joint Commission’s National Patient Safety Goals have long included medication safety, and the FDA has increasingly emphasized the need for safety-engineered medical devices to reduce use errors. This regulatory focus creates a purchasing incentive for hospitals seeking to demonstrate compliance and reduce liability.

Key adjacent markets that could influence adoption include the broader hospital patient monitoring segment and the growing category of connected medical devices within the Internet of Medical Things (IoMT). While SentryFLO is positioned as a dedicated flow control device, its success may depend on integration with these larger hospital data ecosystems. A substitute market is represented by comprehensive smart infusion pump systems, which already include rate control modules for continuous infusions but are often not optimized or used for the specific, rapid bolus administration of IV push medications. This creates the wedge opportunity for a simpler, dedicated device.

Data Accuracy: YELLOW -- Market sizing is inferred from analogous, published third-party reports on related device categories; the specific TAM for IV push safety devices is not publicly defined.

Competitive Landscape

MIXED Racheon's competitive position is defined by its focus on a specific, high-risk procedural error, but the absence of public traction data makes mapping its relative standing against established players a challenge.

A systematic review of venture databases, industry press, and regulatory filings does not surface any direct, named competitor with an identical product proposition [Perplexity Sonar Pro Brief]. This suggests SentryFLO may be targeting a niche within the broader medication administration safety market that is not yet crowded with venture-backed startups. The competitive map must therefore be constructed from adjacent categories and incumbent workflows.

• Incumbent Workflow & Manual Alternatives. The primary competition is the status quo: manual IV push administration by nurses using standard syringes. This method relies on clinician training, vigilance, and manual rate control, a process documented as prone to error. Large medical device distributors like Cardinal Health and McKesson supply the commoditized syringes and infusion sets that constitute the current standard of care.
• Integrated Smart Pump Systems. Companies like Baxter (with its Sigma Spectrum infusion pump) and Becton Dickinson (BD Alaris) offer sophisticated smart infusion pumps that automate and monitor IV medication delivery. These systems are comprehensive but are typically used for longer, continuous infusions in controlled settings like ICUs, not necessarily for the rapid, bedside IV push procedures Racheon targets. They represent a higher-cost, more complex competitive alternative.
• Adjacent Safety & Compliance Software. Platforms like Sentry Data Systems (now part of Craneware) focus on pharmacy charge capture and compliance analytics, not physical flow control [Tracxn, Jul 4, 2026]. Other software startups aim to reduce medication errors through barcode scanning (e.g., Kit Check) or clinical decision support, attacking the problem from the data layer rather than the device layer.

Racheon's stated edge rests on the integration of flow rate control directly into the syringe device, a hardware-based intervention at the point of administration [racheon.com]. If the technology is patented and effective, this could be a defensible product advantage against purely manual or software-based alternatives. However, durability depends on intellectual property protection, which is not publicly confirmed, and the ability to navigate the lengthy FDA clearance process for a Class II medical device. The company's early-stage status and lack of disclosed funding suggest this regulatory and capital moat has not yet been established.

The exposure is significant. Racheon is most vulnerable to competition from the very incumbents it seeks to displace. Large medical device companies possess deep R&D budgets, established regulatory affairs teams, and entrenched relationships with hospital purchasing groups. Should the IV push safety segment prove commercially viable, a company like BD or ICU Medical could develop a competing integrated syringe product faster than Racheon could scale its commercial operations, leveraging existing distribution channels to capture the market.

The most plausible 18-month scenario hinges on validation. If Racheon secures seed funding, completes a pilot study demonstrating error reduction, and files for FDA 510(k) clearance, it could establish itself as the niche leader in procedural safety devices. The winner in this case would be Racheon, if it can move first and secure early design wins with teaching hospitals. Conversely, if the company fails to progress beyond the concept stage or if a pilot reveals technical or usability hurdles, it risks becoming a footnote. The loser would be Racheon, if hospital procurement committees remain unconvinced that a dedicated device solves a problem worth its incremental cost over reinforced training protocols.

Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated product focus and adjacent market segments, as no direct competitors are named in available sources. The landscape of incumbent medical device distributors and smart pump manufacturers is well-documented.

Opportunity

PUBLIC The prize for Racheon is a material reduction in a persistent, costly, and dangerous category of hospital medication errors, a problem that has proven resistant to procedural solutions alone.

The headline opportunity is for SentryFLO to become the de facto hardware standard for IV push medication administration in acute care settings. This outcome is reachable because the problem is well-documented, the proposed solution is a physical intervention at the point of administration, and the regulatory environment increasingly favors technology that demonstrably improves patient safety. The company's clear articulation of its mission,"solving IV push medication errors",targets a specific, high-stakes workflow where errors can lead to direct patient harm [racheon.com, retrieved 2024]. A hardware device that integrates flow rate control offers a tangible, auditable alternative to relying solely on clinician vigilance and manual technique.

Two primary growth scenarios outline plausible paths to scale, though both require significant execution and validation that is not yet publicly documented.

Scenario	What happens	Catalyst	Why it's plausible
Niche Standardization	SentryFLO is adopted as the preferred device for high-risk IV push medications (e.g., opioids, sedatives) within a major hospital system's protocol.	A pilot study demonstrating a measurable reduction in medication errors and associated costs, leading to a system-wide procurement contract.	Hospital systems routinely pilot and adopt new safety devices after positive clinical evidence. The device's description as an "integrated flow rate control" targets a measurable outcome [racheon.com, retrieved 2024].
Regulatory Tailwind	A change in Joint Commission standards or a new FDA guidance emphasizes the use of engineered controls for IV push safety, creating a broader market pull.	Publication of a sentinel event alert or a new safety goal from a major accrediting body highlighting IV push errors.	Regulatory bodies have a history of catalyzing adoption of safety technology (e.g., barcode medication administration). The recent trademark filing for SENTRYFLO indicates active product development aimed at this regulated space [trademarkelite.com, Apr 7, 2026].

Compounding for Racheon would likely follow a classic hardware-enabled software model. Initial device placements generate usage data on administration patterns and error near-misses. This proprietary dataset could inform software analytics for risk prediction and compliance reporting, creating a feedback loop that improves the product and entrenches it within a hospital's safety infrastructure. Over time, a large installed base of devices would create a switching cost moat, as retraining staff and integrating new hardware into established protocols becomes increasingly burdensome. There is no public evidence this flywheel is currently in motion, but the product's integrated nature suggests the potential for such a data layer.

The size of the win can be framed by looking at comparable medical device companies that successfully standardized a safety-critical workflow. While no direct public peer is available for comparison, the valuation of companies that established themselves as category-defining safety solutions in hospital settings often reaches hundreds of millions to low billions of dollars, depending on market penetration. If the Niche Standardization scenario plays out and Racheon captures a meaningful portion of the U.S. acute care market for a critical safety device, the company could represent a valuable, acquisition-target asset for a larger medtech conglomerate seeking to bolster its patient safety portfolio. This outcome is a scenario, not a forecast, and hinges entirely on unproven clinical and commercial execution.

Data Accuracy: YELLOW -- Core product claims are from the company's website and a trademark filing; growth scenarios and market context are inferred from the problem space, not from company-specific traction data.

Sources

PUBLIC

1. [racheon.com, retrieved 2024] Racheon , Improving Outcomes | IV Push Safety | https://racheon.com/

2. [trademarkelite.com, Apr 7, 2026] SENTRYFLO Trademark (USPTO Serial 99456046) | https://www.trademarkelite.com/trademark/trademark-detail/99456046/SENTRYFLO

3. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Brief |

4. [Grand View Research, 2023] Grand View Research, 2023 |

5. [Fortune Business Insights, 2022] Fortune Business Insights, 2022 |

6. [Tracxn, Jul 4, 2026] Sentry Data Systems - 2026 Company Profile & Team | https://tracxn.com/d/companies/sentry-data-systems/__KoKOeH2PI7EFFseS9cLB04AG9HzyMiAVUzF_EMz-WN0